LEADER 00000cam a2200793 i 4500
001 ocn888549876
003 OCoLC
005 20160527040659.7
006 m d
007 cr un|||||||||
008 140806s2014 dcua ob 000 0 eng
016 7 101638824|2DNLM
019 923290897
020 9780309301688
020 0309301688
020 0309301696
020 9780309301695
035 (OCoLC)888549876|z(OCoLC)923290897
040 DNLM|beng|erda|cNLM|dYDXCP|dN$T|dOCLCF|dEBLCP|dOCLCO
042 pcc
049 RIDW
050 4 R852|b.B43 2014
072 7 BUS|x008000|2bisacsh
082 04 174.2|223
090 R852|b.B43 2014
100 1 Beachy, Sarah H.,|0https://id.loc.gov/authorities/names/
no2014050018|eauthor.
245 10 Conflict of interest and medical innovation :|bensuring
integrity while facilitating innovation in medical
research : workshop summary /|cSarah H. Beachy, Adam C.
Berger, and Steve Olson, rapporteurs ; Roundtable on
Translating Genomic-Based Research for Health, Board on
Health Sciences Policy, Institute of Medicine of the
National Academies.
264 1 Washington, D.C. :|bNational Academies Press,|c[2014]
300 1 online resource (1 PDF file (xix, 78 pages)) :
|billustrations
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
347 text file|2rdaft
500 Title from PDF title page.
504 Includes bibliographical references.
505 0 Introduction and overview -- Conflict of interest policies
: an overview -- Perspectives on conflict of interest
policies -- Public perceptions of conflict of interest --
Managing conflict and facilitating innovation.
520 3 Scientific advances such as the sequencing of the human
genome have created great promise for improving human
health by providing a greater understanding of disease
biology and enabling the development of new drugs,
diagnostics, and preventive services. However, the
translation of research advances into clinical
applications has so far been slower than anticipated. This
is due in part to the complexity of the underlying biology
as well as the cost and time it takes to develop a
product. Pharmaceutical companies are adapting their
business models to this new reality for product
development by placing increasing emphasis on leveraging
alliances, joint development efforts, early-phase research
partnerships, and public-private partnerships. These
collaborative efforts make it possible to identify new
drug targets, enhance the understanding of the underlying
basis of disease, discover novel indications for the use
of already approved products, and develop biomarkers for
disease outcomes or directed drug use. While the potential
benefits of collaboration are significant, the fact that
the relationships among development partners are often
financial means that it is vital to ensure trust by
identifying, disclosing, and managing any potential
sources of conflict that could create bias in the research
being performed together. Conflict of Interest and Medical
Innovation is the summary of a workshop convened by the
Institute of Medicine Roundtable on Translating Genomic-
Based Research for Health in June 2013 to explore the
appropriate balance between identifying and managing
conflicts of interest and advancing medical innovation. A
wide range of stakeholders, including government officials,
pharmaceutical company representatives, academic
administrators and researchers, health care providers,
medical ethicists, patient advocates, and consumers, were
invited to present their perspectives and participate in
discussions during the workshop. This report focuses on
current conflict of interest policies and their effect on
medical innovation in an effort to identify best practices
and potential solutions for facilitating innovation while
still ensuring scientific integrity and public trust.
536 This project was supported by contracts between the
National Academy of Sciences and the American Academy of
Nursing (unnumbered contract); American College of Medical
Genetics and Genomics (unnumbered contract); American
Heart Association (unnumbered contract); American Medical
Association (unnumbered contract); American Society of
Human Genetics (unnumbered contract); Association for
Molecular Pathology (unnumbered contract); Blue Cross and
Blue Shield Association (unnumbered contract); College of
American Pathologists (unnumbered contract); Department of
the Air Force (Contract No. FA7014-0-P-0072); Department
of Veterans Affairs (Contract No. VA248-P-1528); Eli Lilly
and Company (unnumbered contract); Genetic Alliance
(unnumbered contract); Health Resources and Services
Administration (Contract No. HHSH250201100119P and
Contract No. HHSH25034017T); International Society for
Cardiovascular Translational Research (unnumbered
contract); Johnson & Johnson (unnumbered contract); The
Kaiser Permanente Program Offices Community Benefit II at
the East Bay Community Foundation (Contract No. 20121257);
Life Technologies (unnumbered contract); National Cancer
Institute (Contract No. HHSN263201200074I, TO#5); National
Coalition for Health Professional Education in Genetics
(unnumbered contract); National Heart, Lung, and Blood
Institute (Contract No. N01-OD-4-2139, TO#275); National
Human Genome Research Institute (Contract No. N01-OD-4-
2139, TO#264 and Contract No. HHSN263201200074I, TO#5);
National Institute of Mental Health (Contract No. N01-OD-4
-2139, TO#275 and Contract No. HHSN263201200074I, TO#5);
National Institute of Nursing Research (Contract No.
HHSN263201200074I, TO#5); National Institute on Aging
(Contract No. N01-OD-4-2139, TO#275 and Contract No.
HHSN263201200074I, TO#5); National Society of Genetic
Counselors (unnumbered contract); Northrop Grumman Health
IT (unnumbered contract); Office of Rare Diseases Research
(Contract No. N01-OD-4-2139, TO#275); Pfizer Inc.
(unnumbered contract); and PhRMA (unnumbered contract).
The views presented in this publication do not necessarily
reflect the views of the organizations or agencies that
provided support for the activity.
588 Description based on version viewed Oct. 9, 2014.
590 eBooks on EBSCOhost|bEBSCO eBook Subscription Academic
Collection - North America
650 0 Medicine|xResearch|0https://id.loc.gov/authorities/
subjects/sh85083097|xMoral and ethical aspects|0https://
id.loc.gov/authorities/subjects/sh00006099|vCongresses.
|0https://id.loc.gov/authorities/subjects/sh99001533
650 0 Conflict of interests|0https://id.loc.gov/authorities/
subjects/sh85030963|vCongresses.|0https://id.loc.gov/
authorities/subjects/sh99001533
650 0 Business and medicine|0https://id.loc.gov/authorities/
subjects/sh2007000119|vCongresses.|0https://id.loc.gov/
authorities/subjects/sh99001533
650 0 Academic-industrial collaboration|0https://id.loc.gov/
authorities/subjects/sh2001000420|vCongresses.|0https://
id.loc.gov/authorities/subjects/sh99001533
650 7 Medicine|xResearch|xMoral and ethical aspects.|2fast
|0https://id.worldcat.org/fast/1015080
650 7 Medicine|xResearch.|2fast|0https://id.worldcat.org/fast/
1015059
650 7 Conflict of interests.|2fast|0https://id.worldcat.org/fast
/874822
650 7 Business and medicine.|2fast|0https://id.worldcat.org/fast
/1742132
650 7 Academic-industrial collaboration.|2fast|0https://
id.worldcat.org/fast/795112
650 12 Biomedical Research.|0https://id.nlm.nih.gov/mesh/D035843
650 22 Conflict of Interest.|0https://id.nlm.nih.gov/mesh/D016265
650 22 Cooperative Behavior.|0https://id.nlm.nih.gov/mesh/D003299
650 22 Industry.|0https://id.nlm.nih.gov/mesh/D007221
650 22 Diffusion of Innovation.|0https://id.nlm.nih.gov/mesh/
D004059
655 4 Electronic books.
655 7 Conference papers and proceedings.|2fast|0https://
id.worldcat.org/fast/1423772
655 7 Conference papers and proceedings.|2lcgft|0https://
id.loc.gov/authorities/genreForms/gf2014026068
700 1 Berger, Adam C.,|0https://id.loc.gov/authorities/names/
no2010177254|eauthor.
700 1 Olson, Steve,|d1956-|0https://id.loc.gov/authorities/names
/n85025654|eauthor.
710 2 Institute of Medicine (U.S.).|bRoundtable on Translating
Genomic-Based Research for Health,|0https://id.loc.gov/
authorities/names/no2008119550|eissuing body.
711 2 Conflict of Interest and Medical Innovation : Ensuring
Integrity While Facilitating Innovation in Medical
Research (Workshop)|d(2013 :|cWashington, D.C.)|0https://
id.loc.gov/authorities/names/no2014083247
776 08 |iPrint version:|z0309301688|z9780309301688
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
search.ebscohost.com/login.aspx?direct=true&scope=site&
db=nlebk&AN=867653|zOnline eBook. Access restricted to
current Rider University students, faculty, and staff.
856 42 |3Instructions for reading/downloading this eBook|uhttp://
guides.rider.edu/ebooks/ebsco
901 MARCIVE 20231220
948 |d20160607|cEBSCO|tebscoebooksacademic|lridw
994 92|bRID
